Ironwood Pharmaceuticals Expands its Pipeline Beyond Linaclotide with Bionomics Deal
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 2 (Table of Contents)
Published: 6 Feb-2012
DOI: 10.3833/pdr.v2012.i2.1675 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to expand its pipeline beyond the late-stage gastrointestinal drug linaclotide, Ironwood Pharmaceuticals has licensed exclusive global rights to develop and commercialise Bionomics’ Phase I anti‐anxiety compound BNC210 and other related compounds...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS